Syschem (India) Limited manufactures Active Pharmaceuticals Ingredients (APIs) and bulk drugs.Product Profile: API/ Intermediates: a) Amoxycillin Tri Hydrate b) Ampicillin Tri Hydrate c) Cloxacillin Sodium d) Dicloxacillin Sodium e) Flucloxacillin Sodium (For export only) f) Cephalexin g) Cefixime h) Cefadroxil i) Distillation of Specialty Solvents – DMF, Acetonitrile, Ethyl Acetate...
Syschem (India) Limited has announced the resignation of its statutory auditor, STAV & Co. The auditor cited the expiration of their Peer Review Certificate, which was not renewed, as the reason for their inability to continue. Importantly, the company clarified there were no concerns related to management, information access, or...
SYSCHEM (INDIA) LIMITED issued a clarification regarding the proposed professional fee for its Statutory Auditor. The company previously disclosed a figure that has now been clarified as 0.025 Cr (originally stated as 2.50 Lakh), plus applicable GST and out-of-pocket expenses. This correction ensures accurate reporting of administrative expenses and auditor...
SYSCHEM's board has approved key leadership changes, subject to shareholder consent. Mr. Suninder Veer Singh will become Managing Director, and Mr. Ranjan Jain will be re-designated as Whole-Time Director, both for five years, with remuneration up to 0.07 Cr per month for three years. The company also appointed M/s Bansal...
Syschem (India) Limited announced that its Statutory Auditor, M/s STAV & Co., has resigned. The auditor stated their inability to continue due to the expiry and non-renewal of their mandatory Peer Review Certificate. This is a compliance-related change for the auditor, not reflecting on the company's financial operations. Syschem is...
SYSCHEM (INDIA) LIMITED issued a clarification regarding its recent Investor Presentation. An inadvertent typographical error led to "Q2 (Quarter-2)" being mentioned instead of "Q1 (Quarter-1)," which pertains to the First Quarter of Financial Year 2026-27. The company clarified that all instances of "Q2" in the presentation should be read as...
